Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Viewpoints: 'Moneyball' and health care; Daschle on diabetes treatment; Elton John and Sen. Nelson on paying for AIDS drugs

Billy Beane's data-driven strategies made him the talk of baseball, the king of the current box office and a highly visible advocate for evidence-based medicine. But Beane's teams have faded since their "Moneyball" heyday -; and evidence-based medicine might not be the home run that some reformers hope it will be.

14 Oct 2011

Echo Therapeutics to begin Symphony tCGM System clinical study in Type 1 and Type 2 diabetes

Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes.

13 Oct 2011

Researchers identify age-dependent beta cell proliferation pathway

As a person ages, the ability of their beta cells to divide and make new beta cells declines. By the time children reach the age of 10 to 12 years, the ability of their insulin-producing cells to replicate greatly diminishes. If these cells, called beta cells, are destroyed-as they are in type 1 diabetes-treatment with the hormone insulin becomes essential to regulate blood glucose levels and get energy from food.

13 Oct 2011

ACR celebrates World Arthritis Day with the theme 'Move to Improve'

The American College of Rheumatology joins organizations from around the world in celebrating World Arthritis Day. Held every year on October 12, this year's theme is "Move to Improve" - focusing on using physical activity to combat arthritis and rheumatic diseases - such as osteoarthritis, rheumatoid arthritis, lupus, gout and psoriatic arthritis.

12 Oct 2011

Endocrine Society releases clinical practice guideline on continuous glucose monitoring

Patients with diabetes face daily challenges in managing their blood glucose levels, and it has been postulated that patients could benefit from a system providing continuous real-time glucose readings. Today, The Endocrine Society released a clinical practice guideline (CPG) providing recommendations on settings where patients are most likely to benefit from continuous glucose monitoring.

12 Oct 2011

Activating brown adipose tissue may help combat obesity, type 2 diabetes

Activating a specialized type of fat, known as brown adipose tissue, may help combat obesity as well as result in better glucose control for type 2 diabetes, according to new research conducted by scientists at the UC Metabolic Diseases Institute.

12 Oct 2011

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

12 Oct 2011

Patients with poorly controlled diabetes may benefit from behavioral, educational interventions

Three randomized controlled trials published Online First today in Archives of Internal Medicine examine the effectiveness of behavioral and educational interventions for patients with poorly controlled diabetes.

11 Oct 2011

World class scientist presents fourth Environmental Microbiology Lecture

World class scientist Professor Willem M. de Vos will explain next Monday how the microbes that are closest to our hearts - gut microbes - could underpin a new way of thinking about human biology. As well as looking at our own genes, we can now include those of our microbes in studies of human health and disease. This is a significant shift in the way we approach human biology.

11 Oct 2011

Sirt1 protein enhances skeletal muscle insulin sensitivity in calorie-restricted mice

The number of individuals with type 2 diabetes is reaching epidemic proportions. One of the main risk factors for developing type 2 diabetes is resistance of cells in the body (particularly liver, fat, and skeletal muscle cells) to the effects of the hormone insulin.

11 Oct 2011

Rare and severe hypoglycemia could be genetic

The life-threatening condition depicts the fact that the body does not have enough energy to function. Scientists at the University of Cambridge say mutations in the AKT2 gene are to blame. Writing in the journal Science, they say there are already cancer drugs which target a similar process.

10 Oct 2011

Merck’s diabetes combo pill gets FDA nod

The U.S. Food and Drug Administration (FDA) has approved Merck & Co.’s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).

10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

People with good vitamin D supply at lower risk of developing Type 2 diabetes

Scientists at the Helmholtz Zentrum München have shown that people with a good vitamin D supply are at lower risk of developing Type 2 diabetes mellitus. The study, which was conducted in cooperation with the German Diabetes Center and the University of Ulm, will be published in the October edition of the renowned scientific journal Diabetes Care.

4 Oct 2011

Stroke more prevalent among Metis than other Manitobans

The stroke rate among Manitoba Metis is nearly 25 percent higher than for other Manitobans, according to a study by the University of Manitoba and the Manitoba Metis Federation (MMF) presented today at the Canadian Stroke Congress.

4 Oct 2011

Men get type 2 diabetes at a lower BMI than women: Study

A latest study reveals that men need to gain little weight in order to develop type 2 diabetes as compared to women. A study carried out by clinical academics at Glasgow University found men developed the disease at a lower Body Mass Index than women, explaining why men have higher rates of diabetes in many parts of the world.

3 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011

Tight blood sugar control fails to improve memory in diabetics

A new study has shown that those with type 2 diabetes do not show slowing of the decline in thinking skills with intense blood sugar control. In fact such intense therapy raises risk of death.

2 Oct 2011

UC San Diego professor receives NIDDK grant to study kidney complications related to diabetes

Kumar Sharma, MD, FAHA, professor of medicine at the University of California, San Diego School of Medicine and director of the Center for Renal Translational Medicine, has received a $5.9 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to study kidney complications related to type 1 and type 2 diabetes.

1 Oct 2011